“You may choose to look the other way, but you can never say again that you did not know.”
— William Wilberforce
Nearly two years after the introduction of COVID-19 biologics around the world, the pharmaceutical industry is facing a waning demand for these products. Scott Rosenstein, a New York-based health care adviser to Eurasia Group said: Supply is exceeding demand in much of the world, even with many countries rolling out booster shots. Once the perception set […]
On May 26, 2022, U.S. Centers for Disease Control (CDC) officials held a press briefing and announced there had been nine cases of monkeypox identified in seven U.S. states and that two licensed smallpox vaccines were in the national stockpile and ready to be distributed.1 The CDC’s director said, “The U.S. has the resources we […]
As COVID-19 vaccine sales continue to soar, Moderna Chief Executive Stephane Bancel’s total personal financial compensation increased by 41 percent in 2021, reaching $18.2 million. The company’s total revenue rose 2,200 percent in 2021, jumping from $803 million to $18.5 billion.1 2 Moderna partnered with the National Institute of Allergy and Infectious Diseases (NIAID), headed […]
Pfizer CEO Albert Bourla, who recently announced that a fourth COVID-19 vaccine dose will be necessary for everyone who has already gotten three doses, was awarded $24.3 million in personal financial compensation in 2021. In addition to his $1.69 million salary, which increased by 15 percent, Bourla took home a cash incentive of $8 million, […]
The U.S. Department of Health and Human Services Office of Inspector General has issued a warning to the public about fraudulent schemes and scams related to COVID-19 services and testing that involve telemarketing calls, text messages, social media platforms, and door-to-door visits.1 At the outset of the SARS-CoV-2 pandemic, there was a proliferation of fraudulent […]
Pfizer, Inc. has withdrawn its emergency use authorization (EUA) application for its experimental BNT162b2 (also known as “Comirnaty”) messenger RNA (mRNA) COVID-19 biologic (developed in collaboration with Germany’s BioNTech) in India.1 Pfizer was the first pharmaceutical company to apply for an EUA to distribute a COVID biologic in India in 2021. However, India’s regulatory agency […]
Since the beginning of the COVID-19 pandemic, public health officials have urged widespread testing for the presence of the SARS-CoV-2 virus that is associated with COVID-19 disease. The two types of coronavirus tests used for diagnosis are laboratory tests and rapid tests, which can either be an antigen test or a Nucleic Acid Amplification Test […]
Based on better than expected sales of its experimental messenger RNA (mRNA) BNT162b2 COVID-19 biologic, New York-based pharmaceutical company Pfizer, Inc. last summer revised projected sales of its experimental drug, also known as “Comirnaty,” from $26 billion to $33.5 billion in 2021. Characterizing second-quarter sales of BNT162b2 as “remarkable,” Pfizer’s chief executive officer (CEO) Albert […]
A former testing site researcher in Texas has alleged that Pfizer’s pre-licensure BNT162b2 (also known as “Comirnaty”) COVID-19 biologic trials included falsification of data, unblinding patients, employing inadequately trained vaccinators, and delays in following up on experimental COVID vaccine adverse reaction reports.1 According to clinical trial researcher Brook Jackson, the incidences occurred during the phase […]
Merck and Pfizer have submitted Emergency Use Authorization (EUA) applications to the U.S. Food and Drug Administration (FDA) to authorize distribution of what would be the first antiviral drug specifically designed to treat COVID-19 disease.1 Merck/Ridgeback Biotherapeutics are seeking EUA approval for Molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral drug originally developed to treat influenza.2 Pfizer […]